Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea
· Delayed Price · Currency is KRW 3,400.00
-80.00 (-2.30%)
May 30, 2025, 3:30 PM KST
Xcell Therapeutics Revenue
In the year 2024, Xcell Therapeutics had annual revenue of 1.93B KRW with 72.11% growth. Xcell Therapeutics had revenue of 476.51M in the quarter ending December 31, 2024, a decrease of -2.22%.
Revenue
1.93B
Revenue Growth
+72.11%
P/S Ratio
21.34
Revenue / Employee
n/a
Employees
n/a
Market Cap
37.19B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| HLB Co., Ltd. | 74.64B |
| Peptron | 4.30B |
| PharmaResearch | 392.31B |